• Dhcr7 Knockout Grass Carp and GCRV Resistance

  2026-10-05

  A 2026 Aquaculture Reports study identified Dhcr7 as an in vivo candidate for GCRV-resistant grass carp breeding. Selected dhcr7 crispants showed approximately 40% higher survival after GCRV-II challenge, stronger antiviral responses, lower viral loads, and less hepatopancreas damage, while growth-related measures were not impaired under the reported study conditions.

• Aclacinomycin A and Persistent rDNA Stress

  2026-10-05

  Aclacinomycin A, also known as Aclarubicin, connects topoisomerase-associated DNA damage with apoptosis and proteasome biology. This article interprets its research value through the distinct lens of persistent ribosomal DNA lesions and PML-nucleolar stress responses.

• How Cholesterol Hinders LNP Intracellular Trafficking

  2026-10-04

  A 2025 International Journal of Pharmaceutics study developed a streptavidin–biotin-DNA tracking platform to examine how lipid nanoparticle composition shapes intracellular trafficking. Its central finding is that higher cholesterol content promoted peripheral early-endosome accumulation, limiting downstream movement of nucleic acid cargo, while DSPC partially reduced this phenotype.

• Fulvestrant (ICI 182,780) Workflow Guide

  2026-10-02

  Build reproducible ER-degradation, MDM2, apoptosis, and chemotherapy-sensitization assays with Fulvestrant. This guide also translates an ER-stress immune study into practical controls while clearly separating validated breast cancer workflows from exploratory cross-domain applications.

• 4-Hydroxytamoxifen (B6167) Workflow Guide

  2026-10-01

  4-Hydroxytamoxifen (B6167) is an estrogen receptor modulator for controlled DMSO-based workflows in breast cancer research, prostate cancer research, and cardiac myocyte studies. It should not be selected for protocols requiring aqueous or ethanol solubility, and the dossier does not establish a validated dose, schedule, or efficacy protocol.

• Partial BACE Inhibition and Synaptic Transmission

  2026-10-01

  Satir et al. examined whether partial β-secretase inhibition can lower amyloid-β secretion without disrupting neuronal communication. Using primary cortical neurons, optical electrophysiology, and three BACE inhibitors, the study identified a functional exposure range in which amyloid beta reduction remained below approximately 50% and synaptic transmission was preserved.

• DNMT3B and Neuroendocrine Prostate Cancer Plasticity

  2026-09-30

  The reference study identifies DNMT3B as a driver of therapy-associated neuroendocrine lineage plasticity and stemness in prostate cancer. Genetic and pharmacologic experiments indicate that suppressing DNMT3B reduces neuroendocrine prostate cancer growth, alters differentiation programs, and promotes apoptosis, providing a rationale for further translational investigation.

• Fulvestrant (ICI 182,780) ER Research Guide

  2026-09-30

  Explore how Fulvestrant (ICI 182,780) supports ERα degradation studies, MDM2 protein degradation research, and chemotherapy-sensitization workflows. This guide also shows how to adapt the compound as a mechanistic control in estrogen–immune signaling assays while avoiding unsupported cross-domain conclusions.

• Multiomics of Crossbreeding and Goose Meat Quality

  2026-09-29

  The reference study combined RNA-seq and nontargeted metabolomics to examine how crossbreeding and sex shape growth, carcass traits, and meat quality in Xingguo gray geese. Its integrated analysis connected production phenotypes with muscle-development and lipid-metabolism signals, providing a molecular framework for interpreting crossbred performance beyond conventional carcass measurements.

• Foretinib (GSK1363089) Research Workflows

  2026-09-29

  Build stronger Foretinib assays by separating tumor cell growth inhibition from true cell killing and by pairing proliferation, motility, invasion, and metastasis endpoints. This workflow combines dose-controlled in vitro experiments with translational guidance for cancer metastasis models and ovarian cancer xenograft studies.

• (S)-(+)-Ibuprofen COX Inhibition Workflows

  2026-09-28

  Build reproducible COX inhibition, inflammation pathway research, and pain mechanism study workflows with the pharmacologically active ibuprofen enantiomer. This guide connects concentration planning, solvent control, assay troubleshooting, and environmental toxicology considerations for more defensible results.

• Foretinib (GSK1363089): Reliable Cell Assays

  2026-09-28

  A practical guide to using Foretinib (GSK1363089), SKU A2974, in cell viability, proliferation, and motility studies. It connects kinase potency and product handling data with scenario-based assay design and interpretation.

• Pazopanib Hydrochloride: Better In Vitro Drug Responses

  2026-09-27

  Use Pazopanib Hydrochloride to probe multi-kinase and anti-angiogenic responses—but distinguish slowed growth from actual cell killing. A paired, time-resolved workflow helps identify which effect your model captures and avoids overinterpreting a single viability endpoint.

• EX 527: Testing SIRT1 in Bone Regeneration

  2026-09-26

  Use EX 527 (SEN0014196) to test whether SIRT1 catalytic activity is necessary for vascular and osteogenic phenotypes—not simply to assume that inhibition reverses activation. This workflow connects p53 acetylation and DNA damage response assays with carefully controlled endothelial–osteogenic experiments.

• Partial BACE Inhibition Preserves Synaptic Transmission

  2026-09-25

  Satir et al. tested whether reducing amyloid-β (Aβ) production with β-secretase inhibitors necessarily disrupts neuronal communication. In cultured rat cortical neurons, Aβ secretion could be reduced by less than 50% without a detectable decrease in synaptic transmission, whereas stronger inhibition was associated with reduced transmission—supporting a dose-sensitive, rather than all-or-none, view of BACE1 inhibition.

7775 records 1/519 page Next 12345 下5页 Last page